Comparison tool

Liraglutide vs Tirzepatide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

LiraglutideTirzepatide

Share this peptide comparison

Property	Liraglutide	Tirzepatide
Category	Weight Loss	Weight Loss
Also known as	Victoza, Saxenda	Mounjaro, Zepbound, LY3298176
FDA approved	Yes	Yes
Clinical status	FDA approved for diabetes as Victoza and weight loss as Saxenda; source also reports Teva generic Saxenda launched Aug 2025. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Weight management, diabetes control, appetite suppression	Weight loss, diabetes management, metabolic health
How it works	Liraglutide is reported to act as a GLP-1 receptor agonist. The source describes glucose-dependent pancreatic insulin signaling, reduced glucagon activity, delayed gastric emptying, and central appetite-related GLP-1 receptor activity in the hypothalamus as mechanisms relevant to glucose control and satiety.	Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved.
Typical dosing	1.8-3 mg daily · Once daily · Subcutaneous injection daily	5-15 mg weekly (after titration) · Once weekly
Research dosing	0.6mg daily (starting) · Once daily · Long-term / chronic use · Subcutaneous injection daily	2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly
Typical duration	Long-term / chronic use	Long-term / chronic use
Administration	Subcutaneous injection daily	Subcutaneous injection weekly
Timing	Morning or evening, consistent daily With or without food	Morning, same day each week With or without food
Evidence level	FDA Approved	FDA Approved
Possible side effects	Nausea (Common; source highlights gastrointestinal effects especially during dose escalation.) Vomiting (Reported gastrointestinal side effect.) Diarrhea (Reported gastrointestinal side effect.) +7 more Constipation (Reported side effect.) Headache (Reported side effect.) Hypoglycemia (Reported with insulin or sulfonylureas.) Pancreatitis (Reported serious adverse event.) Gallbladder disease (Reported serious adverse event.) Acute kidney injury (Reported serious adverse event.) Thyroid C-cell tumors (Boxed warning; source says this is based on rodent studies and that a clear human link has not been established.)	Nausea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.) Diarrhea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.) Vomiting (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) +9 more Constipation (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) Decreased appetite (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) Abdominal pain (Listed in the source adverse-effect information.) Injection site reactions (Listed in the source adverse-effect information.) Hypoglycemia (with insulin/sulfonylureas) (The source specifically gives the insulin/sulfonylurea context.) Pancreatitis (Listed in the source adverse-effect information.) Gallbladder problems (Listed in the source adverse-effect information.) Acute kidney injury (Listed in the source adverse-effect information.) Thyroid C-cell tumors (The source labels this a BOXED WARNING and states a contraindication with MTC/MEN 2.)
Research summary	The source characterizes liraglutide evidence as human clinical evidence rather than preliminary research. It reports that the LEADER trial enrolled 9,340 high-risk participants with type 2 diabetes and found cardiovascular death, heart attack, or stroke occurred in 13.0% with liraglutide versus 14.9% with placebo, published in the New England Journal of Medicine in 2016. For weight outcomes, the source cites the SCALE program, where adults without diabetes lost about 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose. It also notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that labeling includes a boxed warning for thyroid C-cell tumors based on rodent findings without a confirmed human link.	The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results.
References	PubMed New England Journal of Medicine +2 more Drugs.com Pharmacy Times	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Liraglutide

Tirzepatide

Category

Weight Loss

Also known as

Victoza, Saxenda

Mounjaro, Zepbound, LY3298176

FDA approved

Yes

Clinical status

FDA approved for diabetes as Victoza and weight loss as Saxenda; source also reports Teva generic Saxenda launched Aug 2025.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Weight management, diabetes control, appetite suppression

Weight loss, diabetes management, metabolic health

How it works

Liraglutide is reported to act as a GLP-1 receptor agonist. The source describes glucose-dependent pancreatic insulin signaling, reduced glucagon activity, delayed gastric emptying, and central appetite-related GLP-1 receptor activity in the hypothalamus as mechanisms relevant to glucose control and satiety.

Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved.

Typical dosing

1.8-3 mg daily · Once daily · Subcutaneous injection daily

5-15 mg weekly (after titration) · Once weekly

Research dosing

0.6mg daily (starting) · Once daily · Long-term / chronic use · Subcutaneous injection daily

2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly

Typical duration

Long-term / chronic use

Administration

Subcutaneous injection daily

Subcutaneous injection weekly

Timing

Morning or evening, consistent daily

With or without food

Morning, same day each week

With or without food

Evidence level

FDA Approved

Possible side effects

Nausea (Common; source highlights gastrointestinal effects especially during dose escalation.)
Vomiting (Reported gastrointestinal side effect.)
Diarrhea (Reported gastrointestinal side effect.)

+7 more

Constipation (Reported side effect.)
Headache (Reported side effect.)
Hypoglycemia (Reported with insulin or sulfonylureas.)
Pancreatitis (Reported serious adverse event.)
Gallbladder disease (Reported serious adverse event.)
Acute kidney injury (Reported serious adverse event.)
Thyroid C-cell tumors (Boxed warning; source says this is based on rodent studies and that a clear human link has not been established.)

Nausea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.)
Diarrhea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.)
Vomiting (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)

+9 more

Constipation (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)
Decreased appetite (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)
Abdominal pain (Listed in the source adverse-effect information.)
Injection site reactions (Listed in the source adverse-effect information.)
Hypoglycemia (with insulin/sulfonylureas) (The source specifically gives the insulin/sulfonylurea context.)
Pancreatitis (Listed in the source adverse-effect information.)
Gallbladder problems (Listed in the source adverse-effect information.)
Acute kidney injury (Listed in the source adverse-effect information.)
Thyroid C-cell tumors (The source labels this a BOXED WARNING and states a contraindication with MTC/MEN 2.)

Research summary

The source characterizes liraglutide evidence as human clinical evidence rather than preliminary research. It reports that the LEADER trial enrolled 9,340 high-risk participants with type 2 diabetes and found cardiovascular death, heart attack, or stroke occurred in 13.0% with liraglutide versus 14.9% with placebo, published in the New England Journal of Medicine in 2016. For weight outcomes, the source cites the SCALE program, where adults without diabetes lost about 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose. It also notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that labeling includes a boxed warning for thyroid C-cell tumors based on rodent findings without a confirmed human link.

The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results.

References

PubMed New England Journal of Medicine

+2 more

Drugs.com Pharmacy Times

Source Source

+2 more

Source Source

Full profile

View Details